196 related articles for article (PubMed ID: 30082869)
1. Learning from bacterial competition in the host to develop antimicrobials.
Raffatellu M
Nat Med; 2018 Aug; 24(8):1097-1103. PubMed ID: 30082869
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic-Induced Changes in the Intestinal Microbiota and Disease.
Becattini S; Taur Y; Pamer EG
Trends Mol Med; 2016 Jun; 22(6):458-478. PubMed ID: 27178527
[TBL] [Abstract][Full Text] [Related]
3. Heterologous Machine Learning for the Identification of Antimicrobial Activity in Human-Targeted Drugs.
Nava Lara RA; Aguilera-Mendoza L; Brizuela CA; Peña A; Del Rio G
Molecules; 2019 Mar; 24(7):. PubMed ID: 30935109
[TBL] [Abstract][Full Text] [Related]
4. Initial Gut Microbial Composition as a Key Factor Driving Host Response to Antibiotic Treatment, as Exemplified by the Presence or Absence of Commensal Escherichia coli.
Ju T; Shoblak Y; Gao Y; Yang K; Fouhse J; Finlay BB; So YW; Stothard P; Willing BP
Appl Environ Microbiol; 2017 Sep; 83(17):. PubMed ID: 28667114
[TBL] [Abstract][Full Text] [Related]
5. The Intestinal Microbiota: Impacts of Antibiotics Therapy, Colonization Resistance, and Diseases.
Shah T; Baloch Z; Shah Z; Cui X; Xia X
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34202945
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota as a source of novel antimicrobials.
Garcia-Gutierrez E; Mayer MJ; Cotter PD; Narbad A
Gut Microbes; 2019; 10(1):1-21. PubMed ID: 29584555
[TBL] [Abstract][Full Text] [Related]
7. Narrowing the spectrum: the new frontier of precision antimicrobials.
Paharik AE; Schreiber HL; Spaulding CN; Dodson KW; Hultgren SJ
Genome Med; 2017 Dec; 9(1):110. PubMed ID: 29241446
[TBL] [Abstract][Full Text] [Related]
8. Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria.
Hwang IY; Koh E; Kim HR; Yew WS; Chang MW
Drug Resist Updat; 2016 Jul; 27():59-71. PubMed ID: 27449598
[TBL] [Abstract][Full Text] [Related]
9. Bacteriocins and bacteriophage; a narrow-minded approach to food and gut microbiology.
Mills S; Ross RP; Hill C
FEMS Microbiol Rev; 2017 Aug; 41(Supp_1):S129-S153. PubMed ID: 28830091
[TBL] [Abstract][Full Text] [Related]
10. Antibiotics and the Intestinal Microbiome : Individual Responses, Resilience of the Ecosystem, and the Susceptibility to Infections.
Thiemann S; Smit N; Strowig T
Curr Top Microbiol Immunol; 2016; 398():123-146. PubMed ID: 27738912
[TBL] [Abstract][Full Text] [Related]
11. The Threat of Antimicrobial Resistance on the Human Microbiome.
Brinkac L; Voorhies A; Gomez A; Nelson KE
Microb Ecol; 2017 Nov; 74(4):1001-1008. PubMed ID: 28492988
[TBL] [Abstract][Full Text] [Related]
12. A bacteriophage cocktail targeting Escherichia coli reduces E. coli in simulated gut conditions, while preserving a non-targeted representative commensal normal microbiota.
Cieplak T; Soffer N; Sulakvelidze A; Nielsen DS
Gut Microbes; 2018; 9(5):391-399. PubMed ID: 29517960
[TBL] [Abstract][Full Text] [Related]
13. The impact of antimicrobials on gut bacteria: an interview with Karen Scott.
Scott KP
Future Microbiol; 2019 Sep; 14():1081-1082. PubMed ID: 31512517
[No Abstract] [Full Text] [Related]
14. Gut microbiota in autoimmunity: potential for clinical applications.
Kim D; Yoo SA; Kim WU
Arch Pharm Res; 2016 Nov; 39(11):1565-1576. PubMed ID: 27444041
[TBL] [Abstract][Full Text] [Related]
15. Review article: the antimicrobial effects of rifaximin on the gut microbiota.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():3-10. PubMed ID: 26618921
[TBL] [Abstract][Full Text] [Related]
16. Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease.
Babickova J; Gardlik R
World J Gastroenterol; 2015 Oct; 21(40):11321-30. PubMed ID: 26525290
[TBL] [Abstract][Full Text] [Related]
17. Role of antibiotics for treatment of inflammatory bowel disease.
Nitzan O; Elias M; Peretz A; Saliba W
World J Gastroenterol; 2016 Jan; 22(3):1078-87. PubMed ID: 26811648
[TBL] [Abstract][Full Text] [Related]
18. No vacancy: how beneficial microbes cooperate with immunity to provide colonization resistance to pathogens.
Sassone-Corsi M; Raffatellu M
J Immunol; 2015 May; 194(9):4081-7. PubMed ID: 25888704
[TBL] [Abstract][Full Text] [Related]
19. Vitamin A at the interface of host-commensal-pathogen interactions.
Iyer N; Vaishnava S
PLoS Pathog; 2019 Jun; 15(6):e1007750. PubMed ID: 31170262
[No Abstract] [Full Text] [Related]
20. The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment.
Ekmekciu I; von Klitzing E; Fiebiger U; Neumann C; Bacher P; Scheffold A; Bereswill S; Heimesaat MM
Front Cell Infect Microbiol; 2017; 7():167. PubMed ID: 28529928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
